---
title: "礼来的下一代减肥药在试验中取得了接近减肥手术的效果"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/287231633.md"
description: "礼来的下一代肥胖药物 retatrutide 在第三阶段临床试验中显示出良好的结果，达到的减重效果可与减肥手术相媲美。在 TRIUMPH-1 试验中，参与者在 80 周内以 12 毫克剂量平均减重 28.3%。尽管有一些轻微的副作用，但该药物的疗效使其在减重市场中成为强有力的竞争者。礼来股票在盘前交易中上涨了 1%，而竞争对手诺和诺德的股票则小幅下跌"
datetime: "2026-05-21T13:42:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287231633.md)
  - [en](https://longbridge.com/en/news/287231633.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287231633.md)
---

# 礼来的下一代减肥药在试验中取得了接近减肥手术的效果

Eli Lilly reported positive Phase 3 results for its next-generation obesity drug, **retatrutide, which delivered weight-loss results on par with** those of bariatric surgery.

In the TRIUMPH-1 trial, overweight adults, but without diabetes, achieved **meaningful weight loss across all tested doses after 80 weeks**:

-   12 mg dose: average weight loss of 70.3 pounds, or 28.3% of body weight.
-   9 mg dose: average weight loss of 64.4 pounds, or 25.9%.
-   4 mg dose: average weight loss of 47.2 pounds, or 19%

Ahead of the results, _RBC Capital Markets analyst Trung Huynh_ said the **key success range** would be 28% to 30% weight loss.

Lilly's 12 mg dose appears to have cleared the low end of Huynh's bar, with patients losing an average of 28.3% of their body weight over 80 weeks.

"**We're in a zone that's historically been associated with bariatric surgery, and you're getting it with a medicine**," Kenneth Custer, president of Lilly Cardiometabolic Health, told Bloomberg in an interview.

Custer added, "I think we can definitively check the box" based on the data that "retatrutide moves the goalpost on max efficacy."

Retatrutide is a **first-in-class triple hormone receptor agonist**targeting **GIP, GLP-1, and glucagon**, positioning it as potentially superior to current weight-loss drugs such as Lilly's Zepbound, Novo Nordisk's Wegovy, and copycat GLP-1s.

Lilly noted some downsides to taking the drug in the trial:

> _Events of dysesthesia and urinary tract infections were generally mild to moderate, the majority resolved during treatment, and most participants continued taking retatrutide_

In markets, Lilly shares rose about 1% in premarket trading in New York, while shares of the Wegovy competitor, Novo Nordisk, traded in Copenhagen, fell slightly.

**Latest in the GLP-1 space:**

-   HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook

The **key question** is whether bariatric surgery begins to lose favor among patients as next-generation obesity medications replicate, or come close to replicating, surgery-level weight loss without an invasive procedure.

### 相关股票

- [LLY.US](https://longbridge.com/zh-CN/quote/LLY.US.md)
- [ELIL.US](https://longbridge.com/zh-CN/quote/ELIL.US.md)
- [LLYX.US](https://longbridge.com/zh-CN/quote/LLYX.US.md)
- [NVOX.US](https://longbridge.com/zh-CN/quote/NVOX.US.md)
- [RY.US](https://longbridge.com/zh-CN/quote/RY.US.md)
- [NVO.US](https://longbridge.com/zh-CN/quote/NVO.US.md)
- [HIMS.US](https://longbridge.com/zh-CN/quote/HIMS.US.md)

## 相关资讯与研究

- [Nature Medicine：礼来口服减肥药可在停用 GLP-1 类注射剂后，长期维持减肥效果](https://longbridge.com/zh-CN/news/286663823.md)
- [诺和诺德的下一场减肥战：赢下美国之外的市场](https://longbridge.com/zh-CN/news/286740414.md)
- [告别 “溜溜球效应”！礼来口服减肥药及肠道菌群补充剂成对抗体重反弹新答案](https://longbridge.com/zh-CN/news/286211066.md)
- [被礼来反超后，诺和诺德牵手 OpenAI](https://longbridge.com/zh-CN/news/286547688.md)
- [诺和诺德计划推动 Wegovy 口服减肥药登陆美国以外市场](https://longbridge.com/zh-CN/news/286732863.md)